{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:57:47Z","timestamp":1781798267341,"version":"3.54.5"},"reference-count":8,"publisher":"American Society of Hematology","issue":"25","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,18]]},"DOI":"10.1182\/blood.2026034016","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:32:12Z","timestamp":1781796732000},"page":"2993-2994","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["The RELEVANCE of long-term follow-up in follicular lymphoma"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0048-5119","authenticated-orcid":false,"given":"Janlyn","family":"Falconer","sequence":"first","affiliation":[{"name":"Concord Repatriation General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"25","key":"2026061811320587300_bib1","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1182\/blood.2026033126","article-title":"Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis","volume":"147","author":"Gower","year":"2026","journal-title":"Blood"},{"issue":"2","key":"2026061811320587300_bib2","doi-asserted-by":"crossref","first-page":"100080","DOI":"10.1016\/j.bneo.2025.100080","article-title":"Real-world treatment patterns and clinical outcomes in patients with follicular lymphoma: a SEER-Medicare analysis","volume":"2","author":"Chihara","year":"2025","journal-title":"Blood Neoplasia"},{"issue":"31","key":"2026061811320587300_bib3","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.19.01073","article-title":"Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study","volume":"37","author":"Bachy","year":"2019","journal-title":"J Clin Oncol"},{"issue":"7","key":"2026061811320587300_bib4","doi-asserted-by":"crossref","first-page":"e919","DOI":"10.1097\/HS9.0000000000000919","article-title":"Obinutuzumab versus rituximab immunochemotherapy in previously untreated iNHL: final results from the GALLIUM study","volume":"7","author":"Townsend","year":"2023","journal-title":"HemaSphere"},{"issue":"12","key":"2026061811320587300_bib5","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.18.00605","article-title":"First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol"},{"issue":"9873","key":"2026061811320587300_bib6","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"The Lancet"},{"issue":"7","key":"2026061811320587300_bib7","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1200\/JCO.21.01234","article-title":"Response-adapted postinduction strategy in patients with advanced-stage follicular lymphoma: the FOLL12 study","volume":"40","author":"Luminari","year":"2022","journal-title":"J Clin Oncol"},{"issue":"7","key":"2026061811320587300_bib8","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1182\/bloodadvances.2024014840","article-title":"Six-month rituximab-lenalidomide regimen in advanced untreated follicular lymphoma: SAKK 35\/10 trial 10-year update","volume":"9","author":"Kimby","year":"2025","journal-title":"Blood Adv"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/25\/2993\/2528277\/blood_bld-2026-034016-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/25\/2993\/2528277\/blood_bld-2026-034016-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:32:13Z","timestamp":1781796733000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/25\/2993\/569029\/The-RELEVANCE-of-long-term-follow-up-in-follicular"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":8,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2026,6,18]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2026034016","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,18]]},"published":{"date-parts":[[2026,6,18]]}}}